Molecular docking analysis of nuclear factor-κB and genistein interaction in the context of breast cancer.

• Type of Material: Article
• Authors: Vidya Mukund, Banasthali University; Santosh Kumar Behera, Regional Medical Research Centre; Afroz Alam, Banasthali University; P Nagaraju Ganji, Emory University
• Language: English
• Date: 2019
• Publisher: Biomedical Informatics
• Publication Version: Final Published Version
• Copyright Statement: © 2019 Biomedical Informatics
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.6026/97320630015011
• Title of Journal or Parent Work: Bioinformation
• ISSN: 0973-2063
• Volume: 15
• Issue: 1
• Start Page: 11
• End Page: 17
• Keywords: Docking; Genistein; Breast cancer; NF-κB
• Research Categories: Health Sciences, Oncology; Biology, Bioinformatics

Abstract

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a transcription factor and it contributes to breast cancer growth and metastasis. Hence, NF-κB is considered as a target for anti-breast cancer drugs. NF-κB was retrieved from the UniProtKB Data Base with UniProt ID P19838, its energy was minimized and subjected to molecular dynamic simulations using Gromacs v5.0.7 software with GROMOS96 43A1 force field implementing the steepest descent algorithm. The structure of genistein was retrieved from NCBI PubChem database in .sdf format and convert to .pdb format. The genistein compound was docked into the active site of NF-κB proteins with AutoDock tools 1.5. The genistein compound displayed the best binding energies at -6.29 (NF-κB) kcal/mol correspondingly. The binding interactions of this compound with the active site of NF-κB proteins suggested that amino acid residues (Lys52, Ser243, Asp274, Lys, 275) might play a key role in anti-breast cancer activity. Genistein also inhibited the translocation and expression of NF-κB in the nucleus of both breast cancer cell lines. These findings might increase our understanding of the molecular and functional role of NF-κB in breast cancer. It could also help in developing additional druggable NF-κB inhibitors with high potency, specificity and outstanding bioavailability.